Metodi Abadzhiev

[122] Shouval D, Shibolet O. Immunosuppression and HBV reactivation. Semmin Liver

[123] Berger A, Preiser W, Kachel HG, Stumer M, Doerr HW. HBV reactivation after kid‐

[124] Bhamidimarri KB, Pan C. Hepatitis B reactivation during immunosuppression: From

[125] Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and American perspective. Liver Transpl.

[126] Burra P, Germani G, Adam R, et al. Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. J Hepatol. 2013;58:287.

[127] Graxy A, Laffi G, Zignego AL. Hepatitis C virus (HCV) infection: A systematic dis‐

[129] Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection

[130] Zignego AL, Giannini C, Ferri C. Hepatitis C virus-related lymphoproliferative dis‐

[131] Zignego AL, Ganini C, Gragnani L, Piluso A, Fognan E. Hepatitis C virus infection in the immunocompromised host: A complex scenario with variable clinical impact. J

[132] Benhamou Y, Pockros P, Rodriguez-Torres M, Gordon S, Shiffman M, Lirue Y, Afd‐ hai N, Lamon K, Kim Y, Murphy B. The safety and efficacy of viramidine plus Pe‐ gINF alpha-2b versus ribavirin plus PegINF alpha-2b in therapy-naïve patients

infected with HCV: Phase 3 results (VISERI). J Hepatol. 2006;44(Suppl 2):S273. [133] Terrault NA, Adey B. The kidney transplant recipients with hepatitis C infection;

[134] Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies.

[135] Centers for Disease control and Prevention. Testing for HCV infection: An update to guidance for clinicians and laboratorians. MMWR Morb Morta/Wkly Rep.

Pre- and posttransplantation treatment. CJASN. 2007;2(3):563-575.

[128] Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52.

following liver transplantation. Am J Transplant. 2009;9:1707-1713.

orders: An overview. World J Gastroenterol. 2007;13:2467-2478.

pathogenesis to management strategy. N A J Med Sci. 2011;4(1):44-49.

ney transplantation. J Clin Virol. 2005;32(2):162-165.

ease. Mol Aspects Med. 2008;29:85-95

Translac Med. 2012;10:158.

Blood Rev. 2008;22:117-126.

2013;62(18):362-365.

Dis. 2013;33(2):167-177.

126 Immunopathology and Immunomodulation

2005;11:716.

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/61731

#### **Abstract**

Bisphosphonates are used for treatment of different bone conditions, most frequent‐ ly for increasing bone density in osteoporosis patients and for treatment of primary or metastatic bone tumor as well as intake for osteoporosis patients.

The pharmacokinetics of bisphosphonates is well described in order to clarify mech‐ anisms of action of each sub-group according to the classification of these drugs.

Bisphosphonate-induced avascular osteonecrosis is described as phenomenon in the human bones especially observed in human jaws. From pathophysiological point of view this process is studied describing the osteoclast activity inhibition. Several studies and results are stated.

Having in mind that this process occurs in cases that do not include bisphospho‐ nates intake, the American Association of Oral and Maxillofacial surgeons accept a new diagnostic and treatment strategies as well as new name of the disease - Medi‐ cine related osteonecrosis of the jaw.

By comprehensive analysis of all studies by now and cases from our practice, sever‐ al important and significant protocols are introduced in this chapter, effecting diag‐ nosis, treatment preparation, treatment and post-surgical behavior.

**Keywords:** Bisphosphonate-induced osteonecrosis of the jaw, dental implantology, medi‐ cine related osteonecrosis of the jaw

© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
